The trial, sponsored by the Chinese University of Hong Kong, evaluates the efficacy of NCH gel in preventing intrauterine adhesions following ultrasound-guided manual vacuum aspiration for first-trimester miscarriage. If successful, this product could address a significant unmet need in women's reproductive health, particularly in reducing complications associated with IUA. The market for adhesion prevention products is growing, with increasing awareness and demand for minimally invasive solutions in gynecological procedures. Competitive analysis indicates that while there are existing products in the market, the unique formulation and application of NCH gel may provide a differentiated offering. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and the landscape of existing patents related to hyaluronan-based products.